FDA Authority Upheld: Validity of Bioavailability Testing Circulars for Drug Registration

The Supreme Court has affirmed the validity of two Food and Drug Administration (FDA) circulars requiring bioavailability and bioequivalence (BA/BE) testing for certain drug products seeking registration in the Philippines. In Republic v. Drugmaker's Laboratories, Inc. (G.R. No. 190837, March 5, 2014), the Court clarified the scope of the FDA's rule-making authority and settled a dispute that had threatened to weaken safeguards on the quality of generic medicines in the market.

The case arose when two drug manufacturers challenged the FDA's authority to issue these circulars, arguing that only the Secretary of Health possessed such power under the law. The ruling has important implications for pharmaceutical companies, healthcare providers, and patients who rely on the assurance that registered drugs are safe and effective.

Background: The BA/BE Testing Requirement

Bioavailability refers to the rate and extent to which an active ingredient in a drug is absorbed and becomes available at the site of action in the body. Bioequivalence, meanwhile, means that two drug products containing the same active ingredient show no significant difference in how they are absorbed when administered under the same conditions. These tests help ensure that generic versions of drugs perform comparably to their reference products.

The legal framework for drug registration traces back to Republic Act No. 3720, the "Food, Drug, and Cosmetic Act," which created the FDA to establish safety and efficacy standards. In 1989, the Department of Health issued Administrative Order No. 67, which required BA/BE testing for certain pharmaceutical products before they could receive Certificates of Product Registration. However, implementation was deferred because no local facility could conduct such tests at the time.

In 1997, after testing facilities became available in the country, the FDA issued Circular Nos. 1 and 8 to enforce the BA/BE requirement. These circulars operationalized the testing mandate that had already existed under the 1989 Administrative Order.

The Dispute Before the Courts

The respondents, Drugmaker's Laboratories, Inc. and Terramedic, Inc., manufactured a rifampicin suspension used to treat tuberculosis. After their product failed a BA/BE test in 2006, the FDA warned that further renewals of their registration would depend on submitting satisfactory test results. Instead of complying, the companies filed a petition in the Regional Trial Court of Muntinlupa City, seeking to nullify the two FDA circulars.

The RTC ruled in favor of the drug manufacturers, declaring the circulars void. It reasoned that RA 3720 granted rule-making authority only to the Secretary of Health, not to the FDA, and that the circulars were issued without proper hearing and publication. The FDA elevated the case directly to the Supreme Court.

The Supreme Court's Ruling

The Supreme Court reversed the RTC and upheld the validity of the circulars. In resolving the case, the Court distinguished between different types of administrative issuances and clarified which ones require prior notice, hearing, and publication.

Administrative regulations generally fall into three categories. Legislative rules implement a primary law by providing details and can impose obligations on those governed. Interpretative rules merely clarify or explain what an existing law means. Contingent rules depend on the existence of certain facts for their application.

The Court found that Administrative Order No. 67, s. 1989, was the actual legislative rule that introduced the BA/BE testing requirement. Issued by the Secretary of Health under the express authority granted by RA 3720, this order was not challenged by the parties and was presumed valid.

Circular Nos. 1 and 8, s. 1997, by contrast, were not new administrative regulations. They served only to administer and supervise the implementation of the testing requirement already contained in the 1989 Administrative Order. Because these circulars did not create new obligations or affect substantive rights, they did not require prior hearing, consultation, and publication to be valid.

The Court emphasized that the FDA, under Section 4 of RA 3720, has the statutory function to administer and supervise the implementation of the law and its implementing rules. The circulars were a proper exercise of this administrative function.

Practical Takeaways

• The FDA has clear authority to issue circulars that implement and enforce existing regulations, even if the underlying rule-making power belongs to the Secretary of Health.
• Not all agency issuances are "administrative regulations" requiring full notice, hearing, and publication. Circulars that merely operationalize existing rules may be valid without these formalities.
• Drug manufacturers must comply with BA/BE testing requirements for products identified under existing regulations, and failure to submit satisfactory results can justify non-renewal of product registration.
• The ruling reinforces the State's interest in ensuring that generic drugs released to the market are safe and effective, balancing public health concerns with the goal of affordable medicines.
• Companies challenging agency issuances should carefully determine whether the challenged document creates new obligations or simply implements existing ones, as this distinction determines the applicable procedural requirements.

This article is general information and not legal advice. For your specific situation, consult a lawyer or ask ASG Legal AI.